

KCTD21 Rabbit pAb

Catalog # AP98309

Product Information

Application	IHC-P, IHC-F, IF, E
Primary Accession	Q4G0X4
Other Accession	Q4G0X4
Host	Rabbit
Clonality	Polyclonal
Calculated MW	29643
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human KCTD21
Epitope Specificity	1-100/260
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Contains 1 BTB (POZ) domain.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	KCTD21 contains 1 BTB (POZ) domain. The exact function of KCTD21 remains unknown.

Additional Information

Gene ID	283219
Other Names	KCD21_HUMAN; KCTD21; KCASH2 protein; Potassium channel tetramerization domain-containing protein 21; KCD21_MOUSE; potassium channel tetramerization domain containing 21; potassium channel tetramerisation domain containing 21
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	KCTD21
Function	Probable substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex mediating the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes the

ubiquitination of HDAC1. Can function as antagonist of the Hedgehog pathway by affecting the nuclear transfer of transcription factor GLI1; the function probably occurs via HDAC1 down-regulation, keeping GLI1 acetylated and inactive. Inhibits cell growth and tumorigenicity of medulloblastoma (MDB) (PubMed:[21472142](#)).

Tissue Location

Highly expressed in cerebellum and brain. Expression is down-regulated in medulloblastoma

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.